Trichloroacetic acid chemical peel in anti-aging skin therapy in perimenopausal and postmenopausal women

INTERVENTION: The intervention will consist of two stages. The trial participants will be 40 perimenopausal and 40 postmenopausal women. Participants will be qualified for the trial by a cosmetic dermatologist and will be informed about the procedure and will be asked for written consent. After agreeing to participate in the study, trial participants will be randomly divided into two groups in the first and the second stage of the experiment. Randomisation will be based on codes placed in sealed and opaque envelopes. Women randomly included in the groups will not be aware of which group they are in during the study, but after the end of the trial, they will be informed by the study director of which group they were in. Description of the procedure in the experimental group (TCA peel) ‐ the same in the two experimental groups: 1. Make‐up removal and cleansing of the skin. 2. Protecting sensitive areas (eye corner, eyebrows, lips) with petroleum jelly. 3. Chemical peel: three layers of trichloroacetic acid (TCA) at a concentration of 34% will be applied on the skin and rubbed. After each layer, the skin will be hydrated with water. In sensitive skins, the preparation will be rubbed more gently. After the last layer the peeling will be washed off with water and a cream with sunscreen SPF 50+ will be applied. 4. A series of four treatments every 7 days will be conducted. Composition of TCA chemical peel PQ Age Evolution® (PromoItalia, Italy): 1. Trichloroacetic acid 34% (TCA), which removes discolouration and small scars, smoothes the skin, reduces blackheads and affects the synthesis of collagen. 2. Kojic acid 10% with antibacterial and anti CONDITION: Anti‐aging skin therapy in perimenopausal and postmenopausal women ; Skin and Connective Tissue Diseases PRIMARY OUTCOME: ; 1. Skin hydration measured by Corneometer® MC750 B2 (Courage + Khazaka Electronic GmbH, Cologne, Germany) at baseline, 1 month and 3 months after treatment.; 2. Skin elasticity measured by Cutometer® MC750 B2 (Courage + Khazaka Electronic GmbH, Cologne, Germany) at baseline, 1 month and 3 months after treatment; 3. Wrinkle appearance measured by series of photos with the Canon EOS60D camera at baseline, 1 month and 3 months after treatment.; 5. Wrinkle appearance measured by series of photos with the Fujifilm XT1 camera at baseline, 1 month and 3 months after treatment.; 6. Wrinkle appearance measured by series of photos with the DUB SkinScanner 75 at baseline, 1 month and 3 months after treatment.; 7. Wrinkle appearance measured by series of photos with the Artec Leo Easy 3D scanner at baseline, 1 month and 3 months after treatment.; 8. Wrinkle appearance measured by series of photos with the Firely DE300 Digital Video Dermatoscope at baseline, 1 month and 3 months after treatment.; 9. Wrinkle appearance measured by series of photos with the Wrinkle Severity Rating Scale at baseline, 1 month and 3 months after treatment.; 10. Skin discoloration and redness measured by Mexameter® MC750 B2 (Courage + Khazaka Electronic GmbH, Cologne, Germany) at baseline, 1 month and 3 months after treatment.; SECONDARY OUTCOME: ; 1. Skin sebum secretion measured by Sebumeter® MC750 B2 (Courage + Khazaka Electronic GmbH, Cologne, Germany) at baseline, 1 month and 3; months after treatment.; 2. Skin aesthetic improvement measured by the Patient's Aesthetic Improvement Scale (PAIS) at baseline, 1 month and 3 months after; treatment.; 3. Skin aesthetic improvement measured by the Global Aesthetic Improvement Scale (GAIS) at baseline, 1 month and 3 months after; treatment.; 4. Skin aesthetic improvement measured by the Artec Leo Easy 3D scanner at baseline, 1 month and 3 months after treatment.; 5. Skin aesthetic improvement measured by the DUB SkinScanner 75 at baseline, 1 month and 3 months after treatment.; INCLUSION CRITERIA: 1st stage of intervention participant INCLUSION CRITERIA: 1. Age of 40‐58 years and menstruation for the group of perimenopausal women 2. Patient consent for the trial 3. Fitzpatrick skin type 2‐3 4. Contraindications for chemical exfoliation (bacterial, viral or fungal infections, other inflammatory dermatoses such as psoriasis and topical dermatitis, topical retinoids treatment, keloid and scarring tendency) 5. No previous treatments of TCA chemical peels 6. No previous exfoliating and rejuvenating treatments within the previous 6 weeks, including chemical peels, microneedle radiofrequency, fractional ablation laser, microneedling therapy etc 2nd stage of intervention participant INCLUSION CRITERIA: 1. Age 59‐65 years for postmenopausal women 2. Patient consent for the tri